ClinicalTrials.gov record
Completed Phase 3 Interventional

Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy

ClinicalTrials.gov ID: NCT00598793

Public ClinicalTrials.gov record NCT00598793. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 14, 2026, 8:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Biphasic Insulin Aspart 70/30 + Metformin Compared to Insulin Glargine + Metformin in Type 2 Diabetes Failing OAD Therapy

Study identification

NCT ID
NCT00598793
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
242 participants

Conditions and interventions

Interventions

  • biphasic insulin aspart Drug
  • insulin glargine Drug
  • metformin Drug
  • pioglitazone Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2002
Primary completion
Feb 29, 2004
Completion
Feb 29, 2004
Last update posted
Jan 8, 2017

2002 – 2004

United States locations

U.S. sites
27
U.S. states
15
U.S. cities
23
Facility City State ZIP Site status
Novo Nordisk Investigational Site Concord California 94520
Novo Nordisk Investigational Site Los Angeles California 90057
Novo Nordisk Investigational Site Walnut Creek California 94598
Novo Nordisk Investigational Site Melbourne Florida 32901
Novo Nordisk Investigational Site Melbourne Florida 32935
Novo Nordisk Investigational Site West Palm Beach Florida 33401
Novo Nordisk Investigational Site Atlanta Georgia 30318
Novo Nordisk Investigational Site Marietta Georgia 30067
Novo Nordisk Investigational Site Idaho Falls Idaho 83404-7596
Novo Nordisk Investigational Site Chicago Illinois 60607
Novo Nordisk Investigational Site Lexington Kentucky 40504-2681
Novo Nordisk Investigational Site Buffalo New York 14209
Novo Nordisk Investigational Site Asheville North Carolina 28803
Novo Nordisk Investigational Site Canton Ohio 44708
Novo Nordisk Investigational Site Columbus Ohio 43203
Novo Nordisk Investigational Site Medford Oregon 97504
Novo Nordisk Investigational Site Hershey Pennsylvania 17033
Novo Nordisk Investigational Site Greer South Carolina 29651
Novo Nordisk Investigational Site Dallas Texas 75230
Novo Nordisk Investigational Site Dallas Texas 75231
Novo Nordisk Investigational Site Dallas Texas 75246
Novo Nordisk Investigational Site Dallas Texas 75390-8858
Novo Nordisk Investigational Site Houston Texas 77030
Novo Nordisk Investigational Site Midland Texas 79707
Novo Nordisk Investigational Site San Antonio Texas 78229
Novo Nordisk Investigational Site Warrenton Virginia 20186
Novo Nordisk Investigational Site Renton Washington 98055

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00598793, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 8, 2017 · Synced May 14, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00598793 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →